Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will work with Japan-based Sosei Heptares on small molecule drugs for diabetes and metabolic diseases targeting G-protein coupled receptors, the…
Eli Lilly has signed a multi-target collaboration and license agreement with Sosei Heptares to discover and develop GPCR-targeting small molecules for diabetes…
Nxera Pharma achieved a SECOND development milestone in its collaboration with Eli Lilly targeting metabolic diseases (undisclosed payment). The milestone…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sosei Heptares and Eli Lilly entered a multi-target collaboration and license agreement in diabetes and metabolic diseases leveraging Sosei's GPCR-focused StaR/SBDD platform. Sosei received $37M upfront with up to $694M in development and commercial milestones plus tiered royalties on global sales. Since signing, the collaboration has advanced: now-renamed Nxera Pharma (formerly Sosei Heptares) achieved a first development milestone (announced 1 June 2025, undisclosed payment, expected Q3 FY2025) and a second development milestone (announced 8 April 2026, undisclosed payment), both validating its NxWave (formerly StaR/SBDD) GPCR structure-based platform against the metabolic targets. Lilly leads development and commercialization; Nxera remains eligible for up to $694M in remaining development and commercial milestones plus tiered royalties. The collaboration is active and progressing as of June 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sosei Group Corp. (Sosei Heptares) (this deal) | 2022 | $730M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2022 deals · Eli Lilly and Company deals · Metabolic deals